“Every ovarian cancer diagnosis impacts far more than a single patient,” said Sanjeev Luther, chief executive of Ernexa Therapeutics. “It affects families, loved ones and futures.”
Luther said it in a video update on July 14, and the story begins with the problem he was describing. Ovarian cancer remains one of the deadliest cancers affecting women worldwide. Treatment has improved, but many patients relapse, and for those whose disease no longer responds to platinum chemotherapy the options are thin. That is the group Ernexa, a Nasdaq-listed company based in Cambridge, Massachusetts, wants to reach first.
The idea behind ERNA-101
At its heart is a stubborn scientific puzzle. Many ovarian tumours evade the immune system, which scientists call “cold” tumours. ERNA-101 is a cell therapy built to carry an immune-activating protein straight into the tumour’s surroundings, with the aim of making the cancer visible to the body’s defences.
The cells themselves come from induced pluripotent stem cells that Ernexa converts into induced mesenchymal stem cells. The company says this off-the-shelf approach should make manufacturing more consistent and easier to scale, and it avoids harvesting cells from each patient.
So far the evidence is from animal models. Ernexa reports that when ERNA-101 was combined with a PD-1 blocking drug in preclinical ovarian cancer models, tumours cleared completely and every animal survived long term. The company also reports changes in the tumour environment and more immune cells moving in. None of that has been tested in a person.
The road to the clinic
The plan, as the company states it: file an Investigational New Drug application in the third quarter of 2026, then start the first-in-human Phase 1 study in the fourth. The study will treat women with platinum-resistant ovarian cancer. In March Ernexa listed a first look at clinical data in the first half of 2027 and a move into Phase 2 with a possible co-development partner in the second half of that year.
It has a cushion to get there: a recent $10.5 million financing, along with a cut of about 61% in general and administrative spending over the previous year. A pre-IND meeting with the FDA for ERNA-101 is already behind it.
A caution belongs here. Most drugs that look strong in animals do not make it through human trials, and patients should keep working with their own doctors on current treatment rather than waiting for this one.
Ernexa is also developing a second product, ERNA-201, an anti-inflammatory cell therapy aimed at autoimmune disease such as rheumatoid arthritis. It plans a pre-IND meeting with the FDA for that one in the fourth quarter of 2026.
Sources
- Ernexa Therapeutics CEO Corner Highlights Differentiated ERNA-101 Platform as Company Advances Toward Planned First-in-Human Phase 1 Study in 2026
- CEO Discusses ERNA-101's Promise in Ovarian Cancer – ERNA
- Ernexa Therapeutics Highlights Key Catalysts as Company Advances Toward First-in-Human Clinical Trials in 2026
